Johanna Ungerstedt

Professor

Publications

2026

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax, Soren Lehmann, Johanna Ungerstedt, Mattias Mannervik (2026)

HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts Molecular Cancer Therapeutics, Vol. 25, p. 244-256 (Article in journal)

https://dx.doi.org/10.1158/1535-7163.MCT-25-0150

Matilda Kjellander Kynning, Ebba Westerberg, Linda Forsell, Maria Creignou, Daniel Moreno Berggren, Bianca Tesi, Elsa Bernard, Elli Papaemmanuil, Yasuhito Nannya, Lucia Cavelier Franco, Davide Valentini, Eva Hellstrom Lindberg, Seishi Ogawa, Elisabeth Ejerblad, Johanna Ungerstedt (2026)

Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study British Journal of Haematology, Vol. 208, p. 514-523 (Article in journal)

https://dx.doi.org/10.1111/bjh.70264

2025

Bianca Tesi, Anna Robelius, Berivan Baskin, Vladimir Lazarevic, Stefan Deneberg, Martin Höglund, Linda Fogelstrand, Johanna Ungerstedt, Tatjana Pandzic, Magnus Tobiasson, Hege Gravdahl Garelius, Ekaterina Kuchinskaya, Fredrik Persson, Helena Agerstam, Helene Hallböök, Thoas Fioretos, Jessika Nordin, Anna Norberg, Ann-Charlotte Thuresson, Sören Lehmann, Claes Ladenvall, Gisela Barbany, Lovisa Vennström, Elisabeth Ejerblad, Lucia Cavelier, Joerg Cammenga, Martin Jädersten, Eva Hellström-Lindberg, Panagiotis Baliakas (2025)

Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study Clinical Cancer Research, Vol. 31, p. 3062-3071 (Article in journal)

https://dx.doi.org/10.1158/1078-0432.CCR-24-4251

News

20 November 2025

Four LiU researchers recieve funding from the Swedish Cancer Society

Researchers at LiU share SEK 12 million for new projects to improve treatment and quality of life for cancer patients. One of them is Henrik Green, who studies how genetic differences between patients can affect how they react to cancer treatment.